Effects of Low-Level Light Therapy on Resting-State Connectivity Following Moderate Traumatic Brain Injury: Secondary Analyses of a Double-blinded Placebocontrolled Study

Original Research Neuroradiology

Suk-tak Chan\*,
Nathaniel Mercaldo\*,
Maria G. Figueiro Longo,
Jonathan Welt,
Jonathan Welt,
Arman Avesta,
Jarone Lee,
Michael H. Lev,
Eva-Maria Ratai,
Michael R. Wenke,
Blair A. Parry,
Lynn Drake,
Richard R. Anderson,

... See all authors

Deputy Editor: Deputy Editor:

Scientific Editor: DAriane Panzer

\* S.T.C. and N.M. contributed equally to this work.

\*\* B.J.V. and R.G. are co-senior authors.

## Abstract

Patients with moderate traumatic brain injury who were administered low-level light therapy within 72 hours after injury showed increased resting-state brain connectivity as measured with functional MRI during the acute to subacute recovery phases compared with sham-treated patients.

### Background

Low-level light therapy (LLLT) has been shown to modulate recovery in patients with traumatic brain injury (TBI). However, the impact of LLLT on the functional connectivity of the brain when at rest has not been well studied.

#### Purpose

To use functional MRI to assess the effect of LLLT on wholebrain resting-state functional connectivity (RSFC) in patients with moderate TBI at acute (within 1 week), subacute (2–3 weeks), and late-subacute (3 months) recovery phases.

### **Materials and Methods**

This is a secondary analysis of a prospective single-site double-blinded sham-controlled study conducted in patients presenting to the emergency department with moderate TBI from November 2015 to July 2019. Participants were randomized for LLLT and sham treatment. The primary outcome of the study was to assess structural connectivity, and RSFC was collected as the secondary outcome. MRI was used to measure RSFC in 82 brain regions in participants during the three recovery phases. Healthy individuals who did not receive treatment were imaged at a single time point to provide control values. The Pearson correlation coefficient was estimated to assess the connectivity strength for each brain region pair, and estimates of the differences in Fisher z-transformed correlation coefficients (hereafter, z differences) were compared between recovery phases and treatment groups using a linear mixed-effects regression model. These analyses were repeated for all brain region pairs. False discovery rate (FDR)–adjusted P values were computed to account for multiple comparisons. Quantile mixed-effects models were constructed to quantify the

association between the Rivermead Postconcussion Symptoms Questionnaire (RPQ) score, recovery phase, and treatment group.

### Results

RSFC was evaluated in 17 LLLT-treated participants (median age, 50 years [IQR, 25-67 years]; nine female), 21 shamtreated participants (median age, 50 years [IQR, 43-59 years]; 11 female), and 23 healthy control participants (median age, 42 years [IQR, 32–54 years]; 13 male). Seven brain region pairs exhibited a greater change in connectivity in LLLT-treated participants than in sham-treated participants between the acute and subacute phases (range of z differences, 0.37 [95% CI: 0.20, 0.53] to 0.45 [95% CI: 0.24, 0.67]; FDR-adjusted P value range, .010-.047). Thirteen different brain region pairs showed an increase in connectivity in sham-treated participants between the subacute and late-subacute phases (range of z differences, 0.17 [95% CI: 0.09, 0.25] to 0.26 [95% CI: 0.14, 0.39]; FDRadjusted P value range, .020-.047). There was no evidence of a difference in clinical outcomes between LLLT-treated and sham-treated participants (range of differences in medians, -3.54 [95% CI: -12.65, 5.57] to -0.59 [95% CI: -7.31, 8.49]; P value range, .44-.99), as measured according to RPQ scores.

#### Conclusion

Despite the small sample size, the change in RSFC from the acute to subacute phases of recovery was greater in LLLT-treated than sham-treated participants, suggesting that acute-phase LLLT may have an impact on resting-state neuronal circuits in the early recovery phase of moderate TBI.

<u>ClinicalTrials.gov</u> Identifier: NCT02233413

© RSNA, 2024

Supplemental material is available for this article.

Download as PowerPoint

# **Article History**

Received: Apr 22 2023 Revision requested: July 5 2023 Revision received: Feb 28 2024 Accepted: Apr 8 2024 Published online: May 28 2024

#### Abbreviations

BOLD	blood oxygenation level-dependent
FDR	false discovery rate

fMRI	functional MRI
LLLT	low-level light therapy
RPQ	Rivermead Postconcussion Symptoms Questionnaire
RSFC	resting-state functional connectivity
TBI	traumatic brain injury

#### **Metrics**

Downloaded 2,837 times